Opsy logo
Document Processing Files · Ocr Doc Parsing

Opsy

Opsy runs OpsyOne, a Swedish B2B platform for insurance medicine that connects insurers' claims handlers with medical advisers on sickness, accident and personal-injury cases. All data is stored and processed in Sweden, and AI only assists human decisions.

Active GDPR compliant Contact Sales API available Verified by Guidaio
Overview

What is Opsy?

Opsy is a Swedish technology company that describes itself as "den öppna standarden för försäkringsmedicin", the open standard for insurance medicine. Its product, OpsyOne, is a business-to-business platform on which insurers and medical advisers work the same case files: sickness, accident and personal-injury claims. It covers the chain end to end, case administration, medical opinions, quality assurance, regulatory compliance and follow-up, and is used through a web application at app.opsy.one; there is no self-service sign-up.

Six modules carry the product. OpsyScore grades every medical opinion automatically, giving medical managers a basis for coaching and pushing towards assessments that do not depend on which adviser happened to take the case. OpsyVault holds the data: stored in Sweden, no third-party access, full audit trail. OpsyForms serves standardised forms that adapt to the case type and the insurer, cutting back-and-forth. OpsyDocs categorises, tags and structures incoming medical records so a file is built faster and an adviser finds what matters. OpsyIQ shows turnaround times, cost and quality in real time, in the platform or exported through an API to a BI system. OpsyGO, announced for customer availability on 1 October 2026, produces an AI-generated decision basis from the case documentation and the applicable guidelines, either as a standalone service for cases where no physician is required, or embedded to give advisers better material.

AI support was launched across OpsyOne on 19 March 2026 and is implemented customer by customer, with workflow and decision logic fitted to each insurer. The vendor's line is explicit: AI is decision support, and every medical assessment remains a human caseworker decision with full traceability.

Opsy runs an open ecosystem: customers may use their own medical advisers, connect external parties, or draw on Opsy's network, which reached 100 advisers in June 2026, without exclusivity or lock-in. Twenty-nine Swedish insurance and claims companies were on the platform in March 2026. Compliance is presented as built in rather than bolted on, GDPR, the Patient Data Act, DORA, the AI Act, and ISO 27001 certification since 13 October 2025. The publisher is Opsy AB in Stockholm; its listed parent is Opsy Holding AB.

What it does

  • Centralise insurance-medicine case handling between claims handlers and medical advisers in a single shared platform.
  • Score the quality of every medical opinion automatically, so follow-up and coaching rest on measurement rather than impression (OpsyScore).
  • Store and trace medical case data inside Sweden, with no third-party access (OpsyVault).
  • Serve dynamic forms that adapt to the case type and to the insurer, cutting resubmissions and delay (OpsyForms).
  • Categorise, tag and structure incoming medical records automatically (OpsyDocs).
  • Track turnaround times, cost and quality in real time, in the platform or through an API into a BI system (OpsyIQ).
  • Generate an AI-drafted decision basis from the case documentation and the applicable guidelines (OpsyGO, available to customers from 1 October 2026).
Audience

When to use Opsy / When not to

A quick filter to help you decide if Opsy is the right fit.

When to use Opsy

  • Swedish insurers and claims-handling companies working sickness, accident and personal-injury claims: 29 insurance and claims companies were on the platform in March 2026, among them Hedvig Försäkring, SEB Pension och Försäkring, Svedea, Vitea Life, Kommunassurans and three regional Länsförsäkringar companies.
  • Claims handlers who need one shared, traceable workspace with their medical advisers instead of scattered email threads and loose attachments.
  • Chief medical officers and medical advisers who want assessment quality measured rather than assumed: OpsyScore grades every medical opinion automatically and feeds follow-up and coaching.
  • Compliance, risk and data-protection officers operating under GDPR, the Swedish Patient Data Act, DORA and the EU AI Act, who need health data to stay inside Sweden.
  • Independent medical specialists looking for insurance-medicine assignments: the adviser network reached 100 members in June 2026, covering the specialties relevant to personal-injury assessment, with no non-compete clause.

When not to use Opsy

  • Private individuals, patients and claimants: OpsyOne is infrastructure sold to insurers, with no consumer access.
  • Clinical care teams: the platform serves medical assessment for insurance purposes, not the treatment of the patient.
  • Organisations outside Sweden at the time of writing: site, product and customer base are Swedish, and Nordic expansion only began in 2026, with Norway and Finland named as the first markets.
  • Teams that expect self-service sign-up and a published price: entry runs through a mandatory strategy meeting, and no rate is disclosed anywhere on the site.
  • Anyone who needs mobile or offline access: there is no iOS or Android app and no browser extension, access is through the web application only.
Get started

How to use Opsy

A typical end-to-end flow, from setup to results.

  1. Book a 30-minute demo from the home page to see OpsyOne in action, there is no self-service trial to sign up for.
  2. Start with a strategy meeting, in which Opsy reviews the bottlenecks in your current claims-handling process.
  3. Have your environment tailored: permissions, security levels and the connection of the medical advisers you choose.
  4. Go through the compliance check before signing, a legal and technical review with full access to the security architecture.
  5. Complete onboarding and training for claims handlers and administrators; the vendor states OpsyOne is ready to use within a couple of days.
  6. Log in day to day through the web application at app.opsy.one.
  7. Route cases to advisers through OpsyForms, with forms that adapt to the case type and to your company.
  8. Let OpsyDocs categorise and structure incoming medical records, and read the OpsyScore grade on each returned opinion.
  9. Follow turnaround, cost and quality in OpsyIQ, in the platform or piped through the API into your BI system.
  10. Medical advisers take a separate route: they apply through the adviser page, with no non-compete clause attached.
Quick read

Pros & Cons

Pros

  • Explicit data sovereignty, which is rare: storage and processing entirely in Sweden, with the vendor stating that no customer data leaves the country and that no third party has access.
  • ISO 27001 certification with a stated date (13 October 2025), and regulatory compliance presented as part of the platform rather than an add-on, covering GDPR, the Patient Data Act, DORA and the AI Act.
  • AI deliberately kept in a support role: the final medical assessment remains a human caseworker decision, with full traceability on AI-assisted opinions.
  • Open model with no exclusivity and no lock-in on either side, customers may keep their own advisers, and advisers face no non-compete clause.
  • Quality made measurable rather than declarative through automatic scoring of each medical opinion; OpsyScore was recognised at the Insurance Evolution Awards 2026 as technology innovation and marketing innovation of the year in the life category.
  • Verifiable adoption: 29 insurance and claims companies on the platform in March 2026, named customers including Hedvig Försäkring, SEB Pension och Försäkring, Svedea, Vitea Life, Kommunassurans and Länsförsäkringar regional companies, and more than 6,000 closed cases.
  • A legal and technical compliance check offered before contract signature, a stated go-live within a few days, and a listed parent company that publishes quarterly reports and named governance.

Cons

  • No public pricing at all: no pricing page, no rate card, no order of magnitude, an absence confirmed by the site's own sitemap. No free trial or free plan is announced, and there is no self-service sign-up.
  • Very thin public legal documentation: no terms and conditions, no legal notice, no dedicated contact page, and neither a data processing agreement nor a sub-processor list, for a product that handles health data.
  • The privacy policy is short (around 2,700 characters), dated 25 March 2025, states no numeric retention period, and covers the public website rather than platform processing.
  • Site, product and market are entirely Swedish, Nordic expansion only began in 2026 with Norway and Finland, and no interface or processing language is declared anywhere.
  • OpsyGO, the most explicitly AI-driven module, was not yet available at the time of writing, with delivery announced for 1 October 2026.
  • No mobile application and no browser extension; an API is asserted for BI export, but no public documentation of it exists.
  • The publisher is small and loss-making: 7 employees at the end of Q1 2026, EBITDA of -1,487 TSEK for the quarter and 2025 revenue of 6,691 TSEK, figures that belong to the listed parent Opsy Holding AB rather than to Opsy AB alone.
Pricing

Pricing & Plans

No free plan and no free trial are announced, and no price is published: the site carries no pricing page, an absence confirmed by its sitemap. Commercial terms take the form of negotiated B2B contracts entered through a strategy meeting, so no lowest price point can be stated. The only public figures are the annual values of individual customer contracts disclosed in the listed parent's market announcements: approximately SEK 0.8 million a year for Hedvig Försäkring (21 August 2026), and approximately SEK 1 million a year each for SEB Pension och Försäkring AB (27 March 2026), Svedea (28 October 2025) and one unnamed customer (17 December 2025). These are contract values, not list prices, and cannot be converted into a unit rate. Revenue is recognised as cases are closed, which suggests billing tied to case volume.

Prices and plans listed above may evolve. Always check the official pricing page before subscribing.
Trust & Privacy

Data, GDPR & hosting

A consolidated view of how Opsy handles your data.

GDPR overview

GDPR compliance is claimed as built into the product rather than sold as an add-on, alongside the Swedish Patient Data Act, DORA, the EU AI Act and ISO 27001 (certified 13 October 2025). Concrete elements exist. A data protection officer is named, Ludwig Andersson Granados, reachable at dpo@opsy.se or by post at Dataskyddsombud, Opsy AB, Gamla Brogatan 27, 111 20 Stockholm. The policy lists rights of access, rectification, erasure and restriction, names Datainspektionen as the supervisory authority, and states that all processing of personal data takes place within Sweden's borders. As the publisher is established in Sweden, no Article 27 representative is required and none is named. What is missing: no data processing agreement and no sub-processor list are published, and the privacy policy, last updated 25 March 2025, is short and covers the public website rather than the platform.

Who owns the data?

Opsy presents customer data as the customer's own. The OpsyVault module is sold under the line "Er data. Era regler.", your data, your rules, with storage in Sweden, no third-party access and full traceability, and the privacy policy adds that Opsy never sells personal data. Two limits matter. That policy covers the public website, not the processing carried out inside the platform, and no terms and conditions are published anywhere on the site, so no contractual clause on intellectual property or ownership of customer content can be read before negotiation. Ownership is therefore asserted by the vendor rather than documented publicly.

Reuse rights

No terms of service are published, so nothing states what a customer may do with data taken out of the platform, or under what licence Opsy holds it. What the vendor does state is narrower and should be read literally: "ingen information används för extern modellträning", no information is used for external model training, and no customer data leaves Sweden. The qualifier "external" leaves internal training unaddressed, and no opt-out mechanism is documented anywhere. For the website itself, Opsy says it collects only what visitors submit voluntarily, sets no cookies, and never sells personal data. Operational reuse is provided for: OpsyIQ exposes turnaround times, cost and quality in the platform or through an API into the customer's own BI system.

Data retention & training

Retention summary
The published rule is a single sentence: personal data is kept for as long as it is required for the purposes for which it was collected, and Opsy may keep it longer to meet legal requirements or to protect its legal interests. No figure is attached, no retention period in months or years, no purge schedule, no differentiation by data type, and no mention of anonymisation. Deletion is offered as a right: users may request that their data be removed once it is no longer necessary. Two limits are worth noting. This policy governs the public website; there is no published retention policy for the medical case files processed inside the platform. And the policy was last updated on 25 March 2025.
Trains on customer data
No
GDPR contact

Hosting summary

Opsy states that hosting is exclusively Swedish. The home page's OpsyVault block says all data is stored in Sweden, with no third-party access and full traceability. The March 2026 AI announcement is more explicit: all storage and processing take place in Sweden, and no customer data leaves the country. The privacy policy repeats the same for personal data, all processing occurs within Sweden's borders. The commercial argument attached to this is stated plainly by the vendor: no patient file or sensitive personal data should risk ending up in the hands of US authorities. What is not specified matters too. No hosting provider, cloud region or data centre is named anywhere on the site, and no sub-processor list is published. One technical note, so that it is not misread: the marketing website itself resolves to 75.2.60.5, an AWS anycast node geolocated in Seattle. That concerns the public website only, and says nothing about where platform data lives.

Hosting countries
🇸🇪 Sweden
Watch-outs

Things to keep in mind

Risks and trade-offs to weigh before adopting Opsy.

  • The price is only revealed after a sales meeting, so budgeting ahead of that conversation is impossible.
  • No terms and conditions, no legal notice and no dedicated contact page are published, so contractual commitments only surface during negotiation. Note also that the financial figures and governance you can read belong to the listed parent Opsy Holding AB, a small loss-making micro-cap, not to the publisher Opsy AB: supplier viability belongs in your due diligence.
  • Read the training claim literally: the vendor states that no information is used for external model training. Internal training is not addressed, and no opt-out is documented.
  • Neither a data processing agreement nor a sub-processor list is published, for a product that processes health data. Ask for both before any pilot.
  • The privacy policy covers the public website rather than platform processing, dates from 25 March 2025, and sets no numeric retention period.
  • Two vendor claims need checking before you rely on them: OpsyGO is announced for 1 October 2026 rather than shipped, and the ISO 27001 certification is stated with no certificate number and no certification body named on the site.
  • Automatic scoring and an AI-drafted decision basis can quietly become the default answer. The vendor insists the final call stays human, but a caseworker who signs off on a generated basis under time pressure is still the one accountable, and judgement that is not exercised erodes.
Setup

Setup & Integrations

Technical difficulty

Low on the customer's side, because most of the work is done by the vendor. There is no self-service sign-up: a strategy meeting comes first, then Opsy configures permissions, security levels and the connection of the medical advisers you choose, followed by a legal and technical compliance check before signature and by onboarding and training for claims handlers and administrators. Opsy states OpsyOne is ready to use within a couple of days, and promises replacement of an existing system without migration headaches. Access is web-based with nothing to install; an API to a BI system exists but is undocumented.

Deployment

Web appAPI
Company

Behind Opsy

Company name
Opsy AB
Founded
INFORMATION_NOT_FOUND
Country of origin
🇸🇪 Sweden
Headquarters
Gamla Brogatan 27, 111 20 Stockholm
UBO
Arne Thor
UBO country
🇸🇪 Sweden
Domain registrar country
🇸🇪 Sweden

Fundraising

Directed share issue resolved on 15 October 2025 by the board of Opsy Holding AB, the listed parent company rather than the publisher Opsy AB: a maximum of 478,795 shares at SEK 7.31 per share, raising approximately SEK 3.5 million before transaction costs of around SEK 0.1 million.
Subscribers named in the announcement: Erik Norman (273,597 shares) and Alsteron AB (205,198 shares).
The subscription price was set by arm's-length negotiation, at a discount of approximately 10% to the volume-weighted average price over the 15 preceding trading days on Spotlight Stock Market.
Stated use of proceeds: strengthening working capital and continuing the company's expansion.
Dilution of approximately 3.8%: the number of shares and votes rose from 12,218,223 to 12,697,018. The issue was conditional on approval at an extraordinary general meeting expected around 4 November 2025.
Opsy Holding AB is listed on Spotlight Stock Market and reported 12,697,018 shares outstanding as at 31 March 2026.

Social

Official links

Resources

All the official URLs gathered for verification and reference.

Compare

Alternatives

Tools that compete with or complement Opsy.

M Mavera
FAQ

Frequently asked questions

What does OpsyOne actually do?
It is a shared platform on which insurers and medical advisers handle sickness, accident and personal-injury claims: case administration, medical opinions, quality assurance, regulatory compliance and follow-up in one place.
Where is the data stored?
Entirely in Sweden. The vendor states that all storage and processing take place in Sweden, that no customer data leaves the country, and that no third party has access to it (OpsyVault).
Is our data used to train AI models?
Opsy states that no information is used for external model training. Read the wording literally: it addresses external training and says nothing about internal training, and no opt-out mechanism is documented.
Does the AI decide instead of the caseworker?
No. Opsy positions AI as decision support: every medical assessment remains a human caseworker decision, with full traceability.
What is OpsyGO?
A service that produces an AI-generated decision basis from the case documentation and the applicable guidelines. It can be used standalone for cases where no physician is required, or embedded to give medical advisers better material. It is announced for customer availability on 1 October 2026.
What does the platform cost?
No price is published anywhere. Entry runs through a strategy meeting and a negotiated B2B contract, and there is no free plan, no free trial and no self-service sign-up.
Is there a security certification?
Opsy states it has been ISO 27001 certified since 13 October 2025. No certificate number and no certification body are named on the site.
Do we have to use Opsy's medical advisers?
No. Opsy works on an open ecosystem model: customers may use their own advisers, connect external parties, or draw on Opsy's network, with no exclusivity requirement and no lock-in effect.
How long does it take to go live?
The vendor states OpsyOne is ready to use within a couple of days, once the environment has been configured and the legal and technical compliance check has been completed.
Is the product available outside Sweden?
Not yet. The market is Swedish; Nordic expansion started in 2026, with Norway and Finland named as the first markets.
Conclusion

Should you pick Opsy?

Opsy is a narrow, deliberately unglamorous tool: a platform for Swedish insurance medicine, sold to insurers rather than to end users. Within that niche it is coherent. Data sovereignty is stated without hedging, storage and processing in Sweden, no third-party access, no customer data leaving the country, and it is backed by ISO 27001 certification dated 13 October 2025 and by compliance claims covering GDPR, the Patient Data Act, DORA and the AI Act. The AI is deliberately kept in a support role: OpsyGO drafts a decision basis, but the final medical judgement remains a human caseworker's, with an audit trail. The open ecosystem model, with no exclusivity and no lock-in on either the customer or the adviser side, is a genuine differentiator in a market where exclusivity is common.

The weaknesses are just as clear. Pricing is entirely opaque, no page, no range, nothing before a sales meeting. The public legal documentation is very thin: no terms and conditions, no data processing agreement, no sub-processor list, and a privacy policy that covers the website rather than the platform. The scope is Swedish, with Nordic expansion barely started. And OpsyGO, the most explicitly AI-driven module, was not yet delivered when this record was written.

Adoption is real and growing, 29 insurance and claims companies, 100 connected medical advisers, more than 6,000 closed cases, case volume up 19% in Q1 2026, but the vendor remains small: seven employees and a loss-making quarter at the listed parent, Opsy Holding AB. For a Swedish insurer handling personal-injury claims, Opsy is worth a serious look; for anyone outside that description, it is not the tool.